Tabersonine alleviates obesity‐induced cardiomyopathy by binding to Transforming growth factor activated kinase 1 (TAK1) and inhibiting TAK1‐mediated inflammation-Reference-Cited by-同舟云学术

Tabersonine alleviates obesity‐induced cardiomyopathy by binding to Transforming growth factor activated kinase 1 (TAK1) and inhibiting TAK1‐mediated inflammation

Published:2022-11-24 Issue:3 Volume:37 Page:860-871
ISSN:0951-418X
Container-title:Phytotherapy Research
language:en
Short-container-title:Phytotherapy Research

Author:

Chen Yanghao¹²,Lin Wante¹²,Chen Pan²,Ye Bozhi¹²^ORCID,Luo Wu²,Wang Xu²,Huang Weijian¹,Wu Gaojun¹,Liang Guang¹²³^ORCID

Affiliation:

1. Department of Cardiology and The Key Laboratory of Cardiovascular Disease of Wenzhou the First Affiliated Hospital, Wenzhou Medical University Wenzhou China

2. Chemical Biology Research Center School of Pharmaceutical Sciences, Wenzhou Medical University Wenzhou China

3. School of Pharmaceutical Sciences Hangzhou Medical College Hangzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ptr.7666

Reference20 articles.

1. Metabolic Syndrome and Cardiovascular Disease: Challenges and Opportunities